Doxefazepam: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 26: | Line 26: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Doxefazepam.svg|Doxefazepam | |||
File:Doxefazepam3d.png|Doxefazepam | |||
</gallery> | |||
Latest revision as of 02:07, 17 February 2025
Doxefazepam is a benzodiazepine derivative drug developed by Schering AG in the 1970s. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is most commonly used and found in Europe and South America.
Pharmacology[edit]
Doxefazepam is a drug with a high therapeutic index, and a favorable pharmacokinetic profile. It has a half-life of 6.2 hours, which is considered long-acting in comparison to other drugs in its class. It is metabolized in the liver and excreted in the urine.
Medical Uses[edit]
Doxefazepam is primarily used for the treatment of insomnia, including difficulty falling asleep, frequent waking, restlessness, and early-morning awakening. It can also be used to manage anxiety disorders, and in the treatment of alcohol withdrawal.
Side Effects[edit]
Like other benzodiazepines, doxefazepam also has a number of side effects. These can include drowsiness, dizziness, fatigue, and ataxia. It can also cause changes in mood, including feelings of depression. Long-term use can lead to dependence and withdrawal symptoms.
See Also[edit]
References[edit]
<references />


